Cargando…

Immune metabolism in PD-1 blockade-based cancer immunotherapy

Energy metabolism plays an important role in proliferating cells. Recent reports indicate that metabolic regulation or metabolic products can control immune cell differentiation, fate and reactions. Cancer immunotherapy based on blockade of programmed cell death protein 1 (PD-1) has been used worldw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Alok, Chamoto, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Invited Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771015/ https://www.ncbi.nlm.nih.gov/pubmed/32622347 http://dx.doi.org/10.1093/intimm/dxaa046

Ejemplares similares

Current issues and perspectives in PD-1 blockade cancer immunotherapy
por: Chamoto, Kenji, et al.
Publicado: (2020)

Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
por: Kumar, Alok, et al.
Publicado: (2020)

Cancer immunotherapies targeting the PD-1 signaling pathway
por: Iwai, Yoshiko, et al.
Publicado: (2017)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Application of PD-1 Blockade in Cancer Immunotherapy
por: Wu, Xiaomo, et al.
Publicado: (2019)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Metabolism in tumor microenvironment: Implications for cancer immunotherapy
por: Shi, Rongchen, et al.
Publicado: (2020)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
por: Li, Yongshu, et al.
Publicado: (2016)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
por: Ren, Daixi, et al.
Publicado: (2020)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
por: Jia, Long, et al.
Publicado: (2018)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
por: Zhuang, Yuan, et al.
Publicado: (2020)

Microenvironmental regulation of tumour immunity and response to immunotherapy
por: Kockx, Mark M, et al.
Publicado: (2021)

Immunotherapy of alveolar echinococcosis via PD‐1/PD‐L1 immune checkpoint blockade in mice
por: Wang, Junhua, et al.
Publicado: (2018)

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
por: Ge, Yanjun, et al.
Publicado: (2022)

Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy
por: Luby, Angèle, et al.
Publicado: (2021)

Convergence of Cancer Metabolism and Immunity: an Overview
por: Van Dang, Chi, et al.
Publicado: (2018)

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities
por: Dai, Mengyuan, et al.
Publicado: (2022)

Engineered biomaterials for cancer immunotherapy
por: Cai, Lulu, et al.
Publicado: (2020)

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
por: Chandran, Smita S., et al.
Publicado: (2019)

Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy
por: Flies, Dallas B., et al.
Publicado: (2011)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies
por: Ilcus, Cristina, et al.
Publicado: (2017)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Perspectives on the clinical development of immunotherapy in prostate cancer
por: Cordes, Lisa M, et al.
Publicado: (2018)

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
por: Wu, Yilun, et al.
Publicado: (2019)

Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy
por: Jiang, Mingxia, et al.
Publicado: (2021)

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
por: Sato, Hiro, et al.
Publicado: (2020)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_deuithjtconv72d0ljc34rui6r